Personal information

Verified email addresses

Activities

Employment (9)

iNeuro Therapeutics: Cambridge, MA, US

2022-09-01 to present | VP Chemistry
Employment
Source: Self-asserted source
Dario Doller

Alcyoneus ScienceWorks, LLC: Sparta, NJ, US

2015-10-21 to present | Consulting
Employment
Source: Self-asserted source
Dario Doller

Lucy Therapeutics: Cambridge, MA, US

2021-06-28 to 2022-08-31 | VP Drug Discovery
Employment
Source: Self-asserted source
Dario Doller

Sunovion Pharmaceuticals Inc: Marlborough, MA, US

2019-06-24 to 2021-06-25 | Director (Medicinal Chemistry )
Employment
Source: Self-asserted source
Dario Doller

SAGE Therapeutics Inc: Cambridge, MA, US

2017-05-31 to 2019-03-08 | Senior Director, Head of Department (Exploratory Research)
Employment
Source: Self-asserted source
Dario Doller

Concert Pharmaceuticals Inc: Lexington, MA, US

2016-03-21 to 2017-05-30 | Senior Director (Deuterium Platform)
Employment
Source: Self-asserted source
Dario Doller

Lundbeck Research USA Inc: Paramus, NJ, US

2006-02-01 to 2015-10-19 | Director
Employment
Source: Self-asserted source
Dario Doller

Neurogen Corp: Branford, CT, US

2000-01-26 to 2006-01-31 | Associate Director (Medicinal Chemistry)
Employment
Source: Self-asserted source
Dario Doller

Schering-Plough: NJ, NJ, US

1994-09 to 1998-08 (CV and CNS)
Employment
Source: Self-asserted source
Dario Doller

Education and qualifications (2)

Texas A&M University: College Station, TX, US

1989-04 to 1992-08 | Post-doctorate (Chemistry)
Education
Source: Self-asserted source
Dario Doller

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales: Buenos Aires, AR

1983-03 to 1989-04 | Doctor (Quimica Organica)
Education
Source: Self-asserted source
Dario Doller

Professional activities (3)

Faculty Opinions: London, GB

2016-10-19 to present | Faculty Member
Invited position
Source: check_circle
Faculty Opinions

New York Academy of Sciences: New York, NY, US

2013 to present
Membership
Source: Self-asserted source
Dario Doller

American Chemical Society: Washington, DC, US

1990 to present
Membership
Source: Self-asserted source
Dario Doller

Works (4)

A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?

Expert Opinion on Investigational Drugs
2020-12-01 | Journal article
Contributors: Dario Doller; Anton Bespalov; Rob Miller; Malgorzata Pietraszek; Mikhail Kalinichev
Source: check_circle
Crossref

Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases

Journal of Medicinal Chemistry
2019-07-11 | Journal article
Contributors: Quinn Coughlin; Allen T. Hopper; Maria-Jesus Blanco; Vijaya Tirunagaru; Albert J. Robichaud; Dario Doller
Source: check_circle
Crossref

The “Century of Biology” and the Evolving Role of Medicinal Chemists in Neuroscience

ACS Chemical Neuroscience
2017-01-18 | Journal article
Contributors: Dario Doller
Source: check_circle
Crossref

Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action

Neuropharmacology
2014-10 | Journal article
Contributors: Paolo Gubellini; Christophe Melon; Elena Dale; Dario Doller; Lydia Kerkerian-Le Goff
Source: check_circle
Crossref

Peer review (63 reviews for 7 publications/grants)

Review activity for ACS chemical neuroscience. (1)
Review activity for ACS medicinal chemistry letters. (3)
Review activity for ACS omega. (1)
Review activity for ChemMedChem. (2)
Review activity for Faculty Opinions (40)
Review activity for Journal of medicinal chemistry. (13)
Review activity for Neurotherapeutics. (3)